Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 16/20 | 0.40 |
| ▸ | PPARA | Q07869 | 15/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
| ▸ | CTRC | Q99895 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2280554 | 0.76 | SMN1; SMN2 (0.65) | PPARGPPARASMN1; SMN2PTGESALOX5 | |
| SCHEMBL2874282 | 0.71 | PPARG (0.40) | PPARGPPARASMN1; SMN2PTGESALOX5 | |
| SCHEMBL3391374 | 0.70 | PPARG (0.48) | PPARGPPARACTRC | |
| SCHEMBL10638079 | 0.68 | SMN1; SMN2 (0.46) | PPARGPPARASMN1; SMN2 | |
| SCHEMBL2276986 | 0.68 | SMN1; SMN2 (0.61) | PPARGPPARASMN1; SMN2PTGDR2 | |
| SCHEMBL7255301 | 0.67 | PPARG (0.64) | PPARGPPARASMN1; SMN2PTGESALOX5 | |
| SCHEMBL6507757 | 0.67 | TDP1 (0.61) | PPARGPPARASMN1; SMN2 | |
| SCHEMBL7267831 | 0.67 | TPMT (0.41) | SMN1; SMN2 | |
| SCHEMBL11325584 | 0.66 | PPARG (0.50) | PPARGPPARASMN1; SMN2ALOX5FOLH1 | |
| SCHEMBL27602676 | 0.65 | AR (0.51) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998462-B2 | Linkers for anchoring targeting ligands | KEREOS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| EP-2094311-A2 | IMPROVED LINKERS FOR ANCHORING TARGETING LIGANDS | KEREOS, INC. (US) | 2009-09-02 | — | — | EP | disclosed |
| US-20080305037-A1 | LINKERS FOR ANCHORING TARGETING LIGANDS | KEREOS, INC. | 2008-12-11 | — | — | US | disclosed |
| WO-2008070291-A2 | IMPROVED LINKERS FOR ANCHORING TARGETING LIGANDS | KEREOS, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305037-A1 | LINKERS FOR ANCHORING TARGETING LIGANDS | LDLR, HDLBP, FABP1 | PPARG 1620/4885PPARA 970/4885SMN1; SMN2 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.